Yoga Windhu Wardhana
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Yoga Windhu Wardhana has a total of 100 co-authors. Here are the top co-authors by number of shared publications:
- Anis Yohana Chaerunisaa
Department of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, Universitas Padjadjaran, Jatinangor, 45363, Indonesia
10 shared publications - Arif Budiman
Department of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, Universitas Padjadjaran, Bandung, West Java, Indonesia
4 shared publications - Nasrul Wathoni
Department of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, Universitas Padjadjaran, Sumedang, West Java, Indonesia
3 shared publications - Nuur Aanisah
Program Studi S1 Farmasi, Universitas Tadulako, Indonesia
3 shared publications - Agus Rusdin
Department of Pharmaceutical Analysis and Medicinal Chemistry, Faculty of Pharmacy, Universitas Padjadjaran, Jl. Raya Bandung-Sumedang Km. 21, Bandung 45363, Indonesia
2 shared publications Insan Sunan Kurniawansyah
Department of Pharmaceutic and Pharmaceuticals Technology, Faculty of Pharmacy, Universitas Padjadjaran (UNPAD), Indonesia
2 shared publications
Latest Publications
- Open Access
- 1 September 2026
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. ume 20, 1-24
Konjac Glucomannan as a Gel-Forming Biopolymer for Transdermal Drug Delivery: Properties, Formulation Strategies, and Translational Challenges
Konjac glucomannan is a natural polysaccharide increasingly relevant as a matrix forming material for skin applied delivery systems. Its potential is linked to its glucose and mannose backbone, abundant hydroxyl groups, partial acetyl substitution, high molecular weight, and capacity for chain association. These features regulate hydration, swelling, rheology, viscoelasticity, film formation, gelation, and drug release. This narrative review examines konjac glucomannan from a structure based formulation perspective, covering physicochemical attributes, modification strategies, formulation platforms, release behavior, and evaluation requirements. Unlike previous reviews that broadly discuss polysaccharide based transdermal systems or glucomannan across pharmaceutical applications, this review focuses on the relationship between KGM structure, formulation design, and translational performance. Evidence shows its use in films, hydrogel reservoirs, injectable hydrogels, nanofibrous systems, carrier assisted systems, and multilayer matrices. In these platforms, konjac glucomannan functions as a hydration regulating matrix former, release modulator, and structural component. Blending, deacetylation, oxidation, crosslinking, freeze thaw treatment, electrospinning, and layered design can improve mechanical integrity, moisture control, and release performance. However, outcomes vary with molecular attributes, modification conditions, and evaluation methods. Most studies remain focused on material characterization and in vitro release, while durable skin adhesion, ex vivo permeation, skin deposition, long wear performance, and clinically meaningful transport are still insufficiently demonstrated. Further translation requires standardized molecular attributes, ex vivo and in vivo testing, scalable manufacturing, and regulatory evaluation.
- 1 September 2026
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. ume 20, 1-24
Open AccessKonjac Glucomannan as a Gel-Forming Biopolymer for Transdermal Drug Delivery: Properties, Formulation Strategies, and Translational Challenges
Konjac glucomannan is a natural polysaccharide increasingly relevant as a matrix forming material for skin applied delivery systems. Its potential is linked to its glucose and mannose backbone, abundant hydroxyl groups, partial acetyl substitution, high molecular weight, and capacity for chain association. These features regulate hydration, swelling, rheology, viscoelasticity, film formation, gelation, and drug release. This narrative review examines konjac glucomannan from a structure based formulation perspective, covering physicochemical attributes, modification strategies, formulation platforms, release behavior, and evaluation requirements. Unlike previous reviews that broadly discuss polysaccharide based transdermal systems or glucomannan across pharmaceutical applications, this review focuses on the relationship between KGM structure, formulation design, and translational performance. Evidence shows its use in films, hydrogel reservoirs, injectable hydrogels, nanofibrous systems, carrier assisted systems, and multilayer matrices. In these platforms, konjac glucomannan functions as a hydration regulating matrix former, release modulator, and structural component. Blending, deacetylation, oxidation, crosslinking, freeze thaw treatment, electrospinning, and layered design can improve mechanical integrity, moisture control, and release performance. However, outcomes vary with molecular attributes, modification conditions, and evaluation methods. Most studies remain focused on material characterization and in vitro release, while durable skin adhesion, ex vivo permeation, skin deposition, long wear performance, and clinically meaningful transport are still insufficiently demonstrated. Further translation requires standardized molecular attributes, ex vivo and in vivo testing, scalable manufacturing, and regulatory evaluation.
- Open Access
- 1 August 2026
- Published by Taylor & Francis in International Journal of Nanomedicine
- Vol. ume 21, 1-20
Comprehensive Review of Mesoporous Carbon and Mesoporous Silica in Poorly Soluble Drug Delivery: Insights into Drug Loading, Dissolution, Stability, and Pharmacological Performance
One of the major challenges in pharmaceutical drug development is the poor solubility of active compounds. Various strategies have been explored to improve drug solubility, including particle size reduction, crystal form modification, and amorphization. However, these approaches share a common limitation, namely poor physical stability. One promising alternative is the incorporation of drugs into mesoporous materials, which has been shown to improve the pharmaceutical properties of active compounds. The two most commonly studied materials are mesoporous carbon (MC) and mesoporous silica (MS). These materials are known to possess distinct structural and surface characteristics, which ultimately influence the drug delivery behavior of the loaded compounds. Although numerous studies have independently investigated drug delivery using mesoporous materials, direct comparisons between MC and MS remain limited. Therefore, this review aims to provide a comprehensive review of both materials, particularly in terms of their ability to improve the pharmaceutical performance of poorly soluble drugs. Based on the available literature, MC appears to offer higher drug loading efficiency and improved physical stability in many formulations, whereas MS is frequently associated with faster dissolution profiles. Both materials improve drug solubility to a comparable extent and have also demonstrated potential to enhance bioavailability and pharmacological performance. These differences are mainly attributed to surface chemistry, where MC enables strong π-π and hydrophobic interactions, while MS primarily interacts through hydrogen bonding. Overall, both materials offer complementary advantages and should be selected based on formulation goals. This study aligns primarily with SDG 3: Good Health and Well-being by advancing drug formulation technologies to improve the efficacy, stability, and delivery of essential therapeutics.
- 1 August 2026
- Published by Taylor & Francis in International Journal of Nanomedicine
- Vol. ume 21, 1-20
Open AccessComprehensive Review of Mesoporous Carbon and Mesoporous Silica in Poorly Soluble Drug Delivery: Insights into Drug Loading, Dissolution, Stability, and Pharmacological Performance
One of the major challenges in pharmaceutical drug development is the poor solubility of active compounds. Various strategies have been explored to improve drug solubility, including particle size reduction, crystal form modification, and amorphization. However, these approaches share a common limitation, namely poor physical stability. One promising alternative is the incorporation of drugs into mesoporous materials, which has been shown to improve the pharmaceutical properties of active compounds. The two most commonly studied materials are mesoporous carbon (MC) and mesoporous silica (MS). These materials are known to possess distinct structural and surface characteristics, which ultimately influence the drug delivery behavior of the loaded compounds. Although numerous studies have independently investigated drug delivery using mesoporous materials, direct comparisons between MC and MS remain limited. Therefore, this review aims to provide a comprehensive review of both materials, particularly in terms of their ability to improve the pharmaceutical performance of poorly soluble drugs. Based on the available literature, MC appears to offer higher drug loading efficiency and improved physical stability in many formulations, whereas MS is frequently associated with faster dissolution profiles. Both materials improve drug solubility to a comparable extent and have also demonstrated potential to enhance bioavailability and pharmacological performance. These differences are mainly attributed to surface chemistry, where MC enables strong π-π and hydrophobic interactions, while MS primarily interacts through hydrogen bonding. Overall, both materials offer complementary advantages and should be selected based on formulation goals. This study aligns primarily with SDG 3: Good Health and Well-being by advancing drug formulation technologies to improve the efficacy, stability, and delivery of essential therapeutics.
- Open Access
- 1 May 2026
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. ume 20, 1-29
Protection of Hygroscopic Pharmaceutical and Nutraceutical Active Ingredients via Film Coating Technologies: A Review
Hygroscopicity poses a significant challenge in the formulation of pharmaceutical and nutraceutical products, as moisture absorption often leads to chemical degradation, physical instability, and compromised therapeutic efficacy. This narrative literature review, evaluated the comparative effectiveness of various polymeric systems and coating technologies as moisture barriers across diverse dosage forms, including tablets, powders, granules, and particulates. We analyzed a spectrum of barrier materials, including cellulose derivatives, polyvinylpyrrolidone, polyvinyl alcohol (PVA), methacrylates, and shellac, contrasting conventional solvent based techniques (fluid bed, spray drying, freeze drying coating) with advanced methodologies (hot melt coating, electrostatic dry coating, and Atomic Layer Deposition/ALD). Conventional coating systems utilizing HPMC and PVA were found to maintain moisture uptake below 1.5% during long-term storage (40°C/75% RH). However, more advanced strategies demonstrated superior protective capabilities, for instance, hotmelt coating employing lipid-based excipients (Precirol ATO 5) reduced moisture absorption by up to 85% at 75% RH. Furthermore, electrostatic dry coating showed a significant reduction in weight gain, decreasing from 6.5% to 3.3% compared to uncoated cores over a 48-hour period. Notably, ALD provided the most robust protection, preserving the amorphous stability of sensitive particles for up to two years under extreme conditions. This review highlights that film coatings not only mitigate moisture induced degradation but also enhance shelf life and improve the mechanical properties of dosage forms. These results underscore the versatility of coating technologies, enabling formulators to tailor strategies for highly moisture sensitive compounds.
- 1 May 2026
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. ume 20, 1-29
Open AccessProtection of Hygroscopic Pharmaceutical and Nutraceutical Active Ingredients via Film Coating Technologies: A Review
Hygroscopicity poses a significant challenge in the formulation of pharmaceutical and nutraceutical products, as moisture absorption often leads to chemical degradation, physical instability, and compromised therapeutic efficacy. This narrative literature review, evaluated the comparative effectiveness of various polymeric systems and coating technologies as moisture barriers across diverse dosage forms, including tablets, powders, granules, and particulates. We analyzed a spectrum of barrier materials, including cellulose derivatives, polyvinylpyrrolidone, polyvinyl alcohol (PVA), methacrylates, and shellac, contrasting conventional solvent based techniques (fluid bed, spray drying, freeze drying coating) with advanced methodologies (hot melt coating, electrostatic dry coating, and Atomic Layer Deposition/ALD). Conventional coating systems utilizing HPMC and PVA were found to maintain moisture uptake below 1.5% during long-term storage (40°C/75% RH). However, more advanced strategies demonstrated superior protective capabilities, for instance, hotmelt coating employing lipid-based excipients (Precirol ATO 5) reduced moisture absorption by up to 85% at 75% RH. Furthermore, electrostatic dry coating showed a significant reduction in weight gain, decreasing from 6.5% to 3.3% compared to uncoated cores over a 48-hour period. Notably, ALD provided the most robust protection, preserving the amorphous stability of sensitive particles for up to two years under extreme conditions. This review highlights that film coatings not only mitigate moisture induced degradation but also enhance shelf life and improve the mechanical properties of dosage forms. These results underscore the versatility of coating technologies, enabling formulators to tailor strategies for highly moisture sensitive compounds.
- Open Access
- 18 August 2025
- Published by Wiley in ChemistryOpen
- Vol. 14 (12) , e2500332
Deep Eutectic Solvents in Polymeric Drug Carriers: Insights into Release Behavior and Functional Integration
Incorporating deep eutectic solvents (DES) into polymer‐based drug delivery systems (DDS) presents a novel approach to addressing persistent pharmaceutical issues, including low solubility, restricted bioavailability, and unregulated drug release. As environmentally friendly, adjustable, and biocompatible alternatives to traditional organic solvents and ionic liquids, DES possess distinctive physicochemical characteristics—such as strong hydrogen‐bonding ability, low volatility, and structural flexibility—that make them effective as functional excipients. This review consolidates a contemporary understanding of the formulation and performance of polymeric matrices containing DES, highlighting their capacity to alter drug release kinetics, improve solubility, and facilitate dual‐function systems like therapeutic DES (THEDES). A comprehensive overview of the various types of DES and polymeric carriers, their methods of integration, associated physicochemical effects, and drug release mechanisms is provided. Furthermore, the outline problems associated with stability, sterilization, and regulatory considerations. In addition, the most prospective future uses of DES–polymer systems is examined in stimuli‐responsive systems, 3D‐printed scaffolds, and advanced tailored medicine. This article supports the broader polite investigation of polymers and DES in polymeric systems in DDS as a significant step toward safer, more environmentally friendly, high‐efficiency pharmaceutical technologies.
- 18 August 2025
- Published by Wiley in ChemistryOpen
- Vol. 14 (12) , e2500332
Open AccessDeep Eutectic Solvents in Polymeric Drug Carriers: Insights into Release Behavior and Functional Integration
Incorporating deep eutectic solvents (DES) into polymer‐based drug delivery systems (DDS) presents a novel approach to addressing persistent pharmaceutical issues, including low solubility, restricted bioavailability, and unregulated drug release. As environmentally friendly, adjustable, and biocompatible alternatives to traditional organic solvents and ionic liquids, DES possess distinctive physicochemical characteristics—such as strong hydrogen‐bonding ability, low volatility, and structural flexibility—that make them effective as functional excipients. This review consolidates a contemporary understanding of the formulation and performance of polymeric matrices containing DES, highlighting their capacity to alter drug release kinetics, improve solubility, and facilitate dual‐function systems like therapeutic DES (THEDES). A comprehensive overview of the various types of DES and polymeric carriers, their methods of integration, associated physicochemical effects, and drug release mechanisms is provided. Furthermore, the outline problems associated with stability, sterilization, and regulatory considerations. In addition, the most prospective future uses of DES–polymer systems is examined in stimuli‐responsive systems, 3D‐printed scaffolds, and advanced tailored medicine. This article supports the broader polite investigation of polymers and DES in polymeric systems in DDS as a significant step toward safer, more environmentally friendly, high‐efficiency pharmaceutical technologies.
- Open Access
Exploring the Potential of Cellulose Nanocrystals Originated from Ramie (Boehmeria nivea L. Gaud) in Formation of Microspheres for Enhanced Solubility of Furosemide
Cellulose nanocrystals possess unique properties such as high surface area and excellent biocompatibility. They can disrupt strong hydrogen bonds and other intermolecular forces that hinder the solubility of certain molecules thus enhancing the solubility of poorly soluble materials. The main challenge in formulating poorly soluble drugs lies in their limited therapeutic efficacy due to inadequate solubility and bioavailability. Therefore, an innovative approach such as using cellulose nanocrystals to enhance the solubility is highly needed. The aim of this research is to study the potential of ramie (Boehmeria nivea L. Gaud) as a source of cellulose nanocrystals in the development of microspheres for the solubility enhancement of poorly soluble drugs. Nanocrystalline cellulose was isolated from the ramie (Boehmeria nivea L. Gaud) by optimizing hydrolysis conditions with varying acid concentrations and reaction times. Characterizations were performed by measuring particle size, pH, and sulfate content, followed by morphological study by SEM, functional group analysis, and thermal analysis. The use of sulfuric acid in the hydrolysis process of flax cellulose at 45 °C, as the type of acid that gives the best results, at 50% acid concentration for 60 min produces cellulose nanocrystallines with a particle size of 120 nm, sulfate concentration density of 133.09 mmol/kg, crystallinity of 96.2%, and a yield of 63.24 ± 8.72%. Furosemide was used as the poorly soluble drug model and its solubility enhancement in the form of furosemide/RNCC microspheres was evaluated through saturated solubility testing and in vitro dissolution. This study demonstrated that RNCC could improve the solubility of furosemide, which contributes to developing sustainable drug formulations and eco-friendly delivery systems for poorly soluble drugs.
Open AccessExploring the Potential of Cellulose Nanocrystals Originated from Ramie (Boehmeria nivea L. Gaud) in Formation of Microspheres for Enhanced Solubility of Furosemide
Cellulose nanocrystals possess unique properties such as high surface area and excellent biocompatibility. They can disrupt strong hydrogen bonds and other intermolecular forces that hinder the solubility of certain molecules thus enhancing the solubility of poorly soluble materials. The main challenge in formulating poorly soluble drugs lies in their limited therapeutic efficacy due to inadequate solubility and bioavailability. Therefore, an innovative approach such as using cellulose nanocrystals to enhance the solubility is highly needed. The aim of this research is to study the potential of ramie (Boehmeria nivea L. Gaud) as a source of cellulose nanocrystals in the development of microspheres for the solubility enhancement of poorly soluble drugs. Nanocrystalline cellulose was isolated from the ramie (Boehmeria nivea L. Gaud) by optimizing hydrolysis conditions with varying acid concentrations and reaction times. Characterizations were performed by measuring particle size, pH, and sulfate content, followed by morphological study by SEM, functional group analysis, and thermal analysis. The use of sulfuric acid in the hydrolysis process of flax cellulose at 45 °C, as the type of acid that gives the best results, at 50% acid concentration for 60 min produces cellulose nanocrystallines with a particle size of 120 nm, sulfate concentration density of 133.09 mmol/kg, crystallinity of 96.2%, and a yield of 63.24 ± 8.72%. Furosemide was used as the poorly soluble drug model and its solubility enhancement in the form of furosemide/RNCC microspheres was evaluated through saturated solubility testing and in vitro dissolution. This study demonstrated that RNCC could improve the solubility of furosemide, which contributes to developing sustainable drug formulations and eco-friendly delivery systems for poorly soluble drugs.
- Top Cited PapersOpen Access
- 1 July 2025
- Published by Taylor & Francis in International Journal of Nanomedicine
- Vol. ume 20, 8611-8651
A Review on QbD-Driven Optimization of Lipid Nanoparticles for Oral Drug Delivery: From Framework to Formulation
Oral administration is the most preferred route for drug delivery due to its convenience, non-invasiveness, and patient compliance. However, it is challenged by gastrointestinal barriers, enzymatic degradation, and first-pass metabolism, which reduce drug bioavailability. Lipid nanoparticles (LNPs), including solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs), offer a promising strategy to overcome these limitations by enhancing drug stability, permeability, and absorption. The Quality by Design (QbD) framework provides a systematic approach for LNP development to ensure consistent product quality. By promoting process understanding and control, QbD not only supports scientific formulation development but also enhances industrial scalability by reducing the experimental workload, shortening the development time, and lowering the production costs. This review highlights key QbD elements such as the quality target product profile (QTPP), critical quality attributes (CQAs), critical material attributes (CMAs), critical process parameters (CPPs), and design of experiments (DoE) and their roles in guiding formulation and process optimization. The effects of various CMAs and CPPs on the CQAs such as particle size, polydispersity index, encapsulation efficiency, zeta potential, and drug release are discussed. Furthermore, the in vitro, in vivo, and ex vivo performances of optimized LNPs were explored in detail. Overall, QbD offers a robust platform for the rational design and scalable production of high-quality lipid-based drug delivery systems for oral administration.
- 1 July 2025
- Published by Taylor & Francis in International Journal of Nanomedicine
- Vol. ume 20, 8611-8651
Top Cited PapersOpen AccessA Review on QbD-Driven Optimization of Lipid Nanoparticles for Oral Drug Delivery: From Framework to Formulation
Oral administration is the most preferred route for drug delivery due to its convenience, non-invasiveness, and patient compliance. However, it is challenged by gastrointestinal barriers, enzymatic degradation, and first-pass metabolism, which reduce drug bioavailability. Lipid nanoparticles (LNPs), including solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs), offer a promising strategy to overcome these limitations by enhancing drug stability, permeability, and absorption. The Quality by Design (QbD) framework provides a systematic approach for LNP development to ensure consistent product quality. By promoting process understanding and control, QbD not only supports scientific formulation development but also enhances industrial scalability by reducing the experimental workload, shortening the development time, and lowering the production costs. This review highlights key QbD elements such as the quality target product profile (QTPP), critical quality attributes (CQAs), critical material attributes (CMAs), critical process parameters (CPPs), and design of experiments (DoE) and their roles in guiding formulation and process optimization. The effects of various CMAs and CPPs on the CQAs such as particle size, polydispersity index, encapsulation efficiency, zeta potential, and drug release are discussed. Furthermore, the in vitro, in vivo, and ex vivo performances of optimized LNPs were explored in detail. Overall, QbD offers a robust platform for the rational design and scalable production of high-quality lipid-based drug delivery systems for oral administration.
- Open Access
- 20 May 2025
- Published by Brieflands in Journal of Reports in Pharmaceutical Sciences
- Vol. 13 (1)
The Similarity of a Critical Quality Study Among the Ciplukan Extract Capsule from A Laboratory Setting and a Pilot Scale in a Partner Industry
Background: Differences in pharmaceutical product processing and equipment between laboratory development and industrial scale-up can result in dramatically variable quality. Therefore, the quality similarities across pharmaceutical dosage forms must be tested at several facilities. Similarities in the quality of dosage forms for pharmacological treatment derived from herbal ingredients from development and production scale are often overlooked, and no one has published them yet. Methods: A two-level factorial experimental design was used in the laboratory for formulation optimization, with variations in the composition of colloidal silicon dioxide and starch glycolate salts. Quality responses included loss on drying (LOD), flowability, angle of repose, uniformity of capsule weight, and disintegration time. The same responses as the performance of similarity attributes were also evaluated on pilot-scale items from partner businesses. Results: The overall quality response of the tested product met the standards for fine granules and capsules. The composition with the highest attractiveness, according to the program, was F4 at 0.686, based on a pilot-scale formulation at partner industrial facilities. According to a Jaccard similarity of 0.88, the quality test results were quite comparable. A total plate number test was performed to assess the safety of microbiological contamination throughout the processing of all goods, yielding a result of 7.07 × 104, which is still in conformity with the standards of the Indonesian Food and Drug Administration (FDA), namely 107. Conclusions: The Jaccard similarity index for capsule manufacture at two different manufacturing sites is 0.88, indicating an excellent resemblance. This suggests that the process may be repeated in larger quantities.
- 20 May 2025
- Published by Brieflands in Journal of Reports in Pharmaceutical Sciences
- Vol. 13 (1)
Open AccessThe Similarity of a Critical Quality Study Among the Ciplukan Extract Capsule from A Laboratory Setting and a Pilot Scale in a Partner Industry
Background: Differences in pharmaceutical product processing and equipment between laboratory development and industrial scale-up can result in dramatically variable quality. Therefore, the quality similarities across pharmaceutical dosage forms must be tested at several facilities. Similarities in the quality of dosage forms for pharmacological treatment derived from herbal ingredients from development and production scale are often overlooked, and no one has published them yet. Methods: A two-level factorial experimental design was used in the laboratory for formulation optimization, with variations in the composition of colloidal silicon dioxide and starch glycolate salts. Quality responses included loss on drying (LOD), flowability, angle of repose, uniformity of capsule weight, and disintegration time. The same responses as the performance of similarity attributes were also evaluated on pilot-scale items from partner businesses. Results: The overall quality response of the tested product met the standards for fine granules and capsules. The composition with the highest attractiveness, according to the program, was F4 at 0.686, based on a pilot-scale formulation at partner industrial facilities. According to a Jaccard similarity of 0.88, the quality test results were quite comparable. A total plate number test was performed to assess the safety of microbiological contamination throughout the processing of all goods, yielding a result of 7.07 × 104, which is still in conformity with the standards of the Indonesian Food and Drug Administration (FDA), namely 107. Conclusions: The Jaccard similarity index for capsule manufacture at two different manufacturing sites is 0.88, indicating an excellent resemblance. This suggests that the process may be repeated in larger quantities.
- Open Access
- 14 January 2025
- Published by MDPI AG in Pharmaceutics
- Vol. 17 (1) , 102
Current Status of Gout Arthritis: Current Approaches to Gout Arthritis Treatment: Nanoparticles Delivery Systems Approach
The deposition of monosodium urate (MSU) crystals within joint spaces produces a painful inflammatory condition known as gout, a specific form of arthritis. The condition calls for a combined curative and preventive management model. A new development in the approach to gout is that of NLRP3-targeted biologic agents, such as monoclonal therapies, to provide more accurate treatment by blocking specific pro-inflammatory cytokines. Nanoparticle drug delivery enhances biological availability and delivery to targets, which may increase therapeutic efficacy and decrease general toxicity. The preventive approach again cannot be ignored, mainly keeping up certain modifications in diet and weight, along with pharmacological therapies to reduce uric acid (UA) levels and to decrease the frequency of acute attacks. The advancement of genetic profiling of patients and biomarker discoveries drives the trend towards building individualized medicine and care, quickly gaining ground as the most effective method of delivering treatments to individual patients, moving away from one-size-fits-all treatments. The following paper aims to provide an updated account of the management of gout with a focus on recent developments, in order to enhance these approaches, the quality of life for patients with gout, and the standard of gout treatment.
- 14 January 2025
- Published by MDPI AG in Pharmaceutics
- Vol. 17 (1) , 102
Open AccessCurrent Status of Gout Arthritis: Current Approaches to Gout Arthritis Treatment: Nanoparticles Delivery Systems Approach
The deposition of monosodium urate (MSU) crystals within joint spaces produces a painful inflammatory condition known as gout, a specific form of arthritis. The condition calls for a combined curative and preventive management model. A new development in the approach to gout is that of NLRP3-targeted biologic agents, such as monoclonal therapies, to provide more accurate treatment by blocking specific pro-inflammatory cytokines. Nanoparticle drug delivery enhances biological availability and delivery to targets, which may increase therapeutic efficacy and decrease general toxicity. The preventive approach again cannot be ignored, mainly keeping up certain modifications in diet and weight, along with pharmacological therapies to reduce uric acid (UA) levels and to decrease the frequency of acute attacks. The advancement of genetic profiling of patients and biomarker discoveries drives the trend towards building individualized medicine and care, quickly gaining ground as the most effective method of delivering treatments to individual patients, moving away from one-size-fits-all treatments. The following paper aims to provide an updated account of the management of gout with a focus on recent developments, in order to enhance these approaches, the quality of life for patients with gout, and the standard of gout treatment.
- Open Access
Impact of Solvent-Mediated Phase Transitions by Artificial Gastrointestinal Buffers on Efavirenz Polymorphs
The implications of various pH solutions in the gastrointestinal fluid system as solvent-mediated phase transitions on concurrent polymorphism transformation, notably metastable polymorphic forms of Efavirenz (EFV), has never been investigated. The impact will be shifting in the solubility and crystallinity of EFV polymorphisms, particularly metastable Forms II and III. EFV’s metastable form is generated by recrystallization with n-hexane and methanol, which were all immersed in artificial digestion buffer solutions for 10 and 100 h, respectively. Form II showed a 9–13.2% increase in solubility, whereas Form III increased by 2–7.3% over Form I. Interestingly, Form II revealed decreased crystallinity, but Form III tended to retain or slightly increase. In acidic solutions, all metastable polymorphs had the highest solubility and crystallinity. Form III appears to have a lower impact on phase transitions owing to pH variations than Form II. These findings indicate that variability in the pH of digestive secretions are essential steps in developing successful pharmaceutical formulations. Finally, our findings provide information on the complex interaction between solvents, pH variations, and EFV polymorphs. The findings identified the importance of these factors in the development of successful pharmaceutical formulations.
Open AccessImpact of Solvent-Mediated Phase Transitions by Artificial Gastrointestinal Buffers on Efavirenz Polymorphs
The implications of various pH solutions in the gastrointestinal fluid system as solvent-mediated phase transitions on concurrent polymorphism transformation, notably metastable polymorphic forms of Efavirenz (EFV), has never been investigated. The impact will be shifting in the solubility and crystallinity of EFV polymorphisms, particularly metastable Forms II and III. EFV’s metastable form is generated by recrystallization with n-hexane and methanol, which were all immersed in artificial digestion buffer solutions for 10 and 100 h, respectively. Form II showed a 9–13.2% increase in solubility, whereas Form III increased by 2–7.3% over Form I. Interestingly, Form II revealed decreased crystallinity, but Form III tended to retain or slightly increase. In acidic solutions, all metastable polymorphs had the highest solubility and crystallinity. Form III appears to have a lower impact on phase transitions owing to pH variations than Form II. These findings indicate that variability in the pH of digestive secretions are essential steps in developing successful pharmaceutical formulations. Finally, our findings provide information on the complex interaction between solvents, pH variations, and EFV polymorphs. The findings identified the importance of these factors in the development of successful pharmaceutical formulations.
- Open Access
- 24 December 2024
- Published by MDPI AG in Preprints.org
Moisture Protection for Granules Containing Deep Seawater Concentrate
Background: Concentrated deep seawater is rich in minerals, including magnesium (Mg), sodium (Na), potassium (K), and calcium (Ca), commonly used in multivitamin. When these minerals are served as solid forms, their nature are highly hygroscopic, making them prone in absorbing moisture. Consequently, development of a non-hygroscopic solid dosage form derived from mineral-rich concentrated deep seawater is highly in need. Methods: Prior formulation stage, the quality of the deep seawater was verified through physical, chemical, and biological assessments based on available Quality Standard. To provide solid form with moisture resistance, the deep seawater concentrate was formulated into granule by using fillers: Avicel® PH 102 and Lactose with 10% Florite® as dessicant. Comprehensive evaluations of the granules including organoleptic, physical properties such as Flow rate, Angle of repose, Compressibility and Loss on Drying had been conducted. These parameters were also evaluated during stability study for five months of storage. Advance verifications were also been performed by using instruments such as Differential Scanning Calorimetry (DSC), X-ray Diffraction (XRD), and Scanning Electron Microscopy (SEM). Results: The results indicated that the optimum moisture protection was provided by granule formulation using Avicel® PH 102 as filler (G-Av) either with or without addition of Florite® 10%. Stability study showed that the protection was effective either in ambient temperature or climatic chamber storage. Conclusions: Avicel PH 102 as filler provided moisture protection for deep seawater granules which highly hygroscopic in nature.
- 24 December 2024
- Published by MDPI AG in Preprints.org
Open AccessMoisture Protection for Granules Containing Deep Seawater Concentrate
Background: Concentrated deep seawater is rich in minerals, including magnesium (Mg), sodium (Na), potassium (K), and calcium (Ca), commonly used in multivitamin. When these minerals are served as solid forms, their nature are highly hygroscopic, making them prone in absorbing moisture. Consequently, development of a non-hygroscopic solid dosage form derived from mineral-rich concentrated deep seawater is highly in need. Methods: Prior formulation stage, the quality of the deep seawater was verified through physical, chemical, and biological assessments based on available Quality Standard. To provide solid form with moisture resistance, the deep seawater concentrate was formulated into granule by using fillers: Avicel® PH 102 and Lactose with 10% Florite® as dessicant. Comprehensive evaluations of the granules including organoleptic, physical properties such as Flow rate, Angle of repose, Compressibility and Loss on Drying had been conducted. These parameters were also evaluated during stability study for five months of storage. Advance verifications were also been performed by using instruments such as Differential Scanning Calorimetry (DSC), X-ray Diffraction (XRD), and Scanning Electron Microscopy (SEM). Results: The results indicated that the optimum moisture protection was provided by granule formulation using Avicel® PH 102 as filler (G-Av) either with or without addition of Florite® 10%. Stability study showed that the protection was effective either in ambient temperature or climatic chamber storage. Conclusions: Avicel PH 102 as filler provided moisture protection for deep seawater granules which highly hygroscopic in nature.